ReviewFrontiers in veterinary science2025
Extracellular vesicles in stem cell-based gonadal regeneration: mechanisms, therapeutic potential, and translational challenges.
Review in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonadal dysfunction resulting from conditions such as premature ovarian insufficiency, chemotherapy-induced damage, or genetic disorders often leads to infertility and hormone imbalance. Although assisted reproductive technologies and hormone replacement therapies mitigate clinical symptoms, they remain incapable of reinstating native gonadal architecture and physiological function. In recent years, stem cell-based therapies, particularly those employing mesenchymal stem cells (MSCs), have demonstrated regenerative potential. However, limitations including poor engraftment, potential tumorigenicity, and ethical concerns, have accelerated the paradigm shift toward extracellular vesicles (EVs) as a safer, cell-free alternative. EVs derived from MSCs are membrane-bound nanovesicles enriched with regulatory microRNAs, proteins, and lipids that exert potent paracrine effects. These vesicles modulate apoptosis, inflammation, fibrosis, and angiogenesis. MSC-EVs can restore folliculogenesis, support spermatogenesis, and normalize hormonal profiles in preclinical models of ovarian and testicular failure. Notably, EVs derived from adipose tissue, bone marrow, placenta, or amniotic membrane exhibit regenerative potential while mitigating the risks associated with live-cell transplantation. This review synthesizes current advances in MSC-EV-based therapies for gonadal regeneration, highlighting their integration into reproductive tissue engineering. Incorporating EVs into decellularized extracellular matrix scaffolds offers promising strategies for targeted tissue repair, extending their application in organoid systems for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.